In streptozotocin-induced rats, apigenin–solid lipid nanoparticles effectively prevent diabetic nephropathy by inhibiting the release of inflammatory molecules and reducing the lipid peroxidation process through the NRF2/HO-1/NF-kB-signaling pathway [77]. This evidence concerns the gene NFE2L2 and diabetic kidney disease.